Selling Shareholder Update: SILV Fund to Resell $4.3M in ADSs, Adding to Dilution Risk
QNRX is trading near its 52-week low of $4.55 (8.4% above the low) on light trading volume (0.3× avg).
Summary
A new selling shareholder, SILV Fund Ltd, has been added to an existing resale prospectus, intending to sell $4.3 million worth of ADSs, which is a significant portion of Quoin Pharmaceuticals' market cap.
Key Events · Ownership and Investor Activity · QNRX
-
New Selling Shareholder Added
SILV Fund Ltd has been added to the existing resale prospectus, replacing Point72 Associates, LLC.
-
Significant Share Resale Planned
SILV Fund Ltd intends to sell all 909,090 American Depositary Shares (ADSs) it beneficially owns.
-
Substantial Market Overhang
The planned sale is valued at approximately $4.3 million, representing a significant portion of the company's market capitalization.
-
Going Concern Context
This potential selling pressure comes as the company faces a going concern warning, as disclosed in recent financial filings.
Analysis · QNRX · Life Sciences
This prospectus supplement updates an existing resale offering, adding SILV Fund Ltd as a selling shareholder. The fund intends to sell all 909,090 ADSs it beneficially owns, valued at approximately $4.3 million based on the last closing price. This represents a substantial portion of the company's market capitalization and adds significant selling pressure, especially for a company that recently issued a going concern warning.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QNRX was trading at $4.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.4M. The 52-week trading range was $4.55 to $41.80. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.